Come a long way, still a ways to go: from predicting and preventing fluoropyrimidine toxicity to increased efficacy?

Pharmacogenomics. 2018 Jun 1;19(8):689-692. doi: 10.2217/pgs-2018-0040. Epub 2018 May 22.

Authors

Seid Hamzic^{1

2}, Ursula Amstutz¹, Carlo R Largiadèr¹

Affiliations

¹ University Institute of Clinical Chemistry, Inselspital Bern University Hospital, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland.
² Graduate School for Cellular & Biomedical Sciences, University of Bern, Freiestrasse 1, CH-3012 Bern, Switzerland.

PMID: 29783877
DOI: 10.2217/pgs-2018-0040

No abstract available

Keywords: 5-FU; BSA-based dosing; DPYD; TDM; capecitabine; pharmacogenetics.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Capecitabine / adverse effects*
Drug-Related Side Effects and Adverse Reactions / genetics*
Female
Fluorouracil / adverse effects*
Humans
Male
Pharmacogenetics / methods
Polymorphism, Single Nucleotide / genetics

Substances

Capecitabine
Fluorouracil